Short- and Medium-term Outcomes of New Generation Biological Aortic Valves in Aortic Valve Replacement Surgery
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Echocardiography
- Sponsor
- Centre Hospitalier Universitaire, Amiens
- Enrollment
- 172
- Locations
- 1
- Primary Endpoint
- Variation of mortality rate between both groups
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Over the past decade, aortic valve replacement surgery has undergone significant changes in terms of both the approaches and the prostheses used. In parallel with the historical biological prostheses for aortic valve surgery, a new generation of bioprostheses has been marketed since 2008, with the entry of these new prostheses in the armatorium of the Amiens-Picardy University Hospital since 2010. These are rapid deployment prostheses or prostheses without sutures. As a result, patients undergoing aortic valve replacement have been able to benefit from this type of bioprosthesis during their procedures. There are few publications reporting the 5-year follow-up of these bioprostheses. The investigators therefore decided to follow up patients operated on by a new generation bioprosthesis to study the 5-year survival and the functioning of their bioprostheses, in order to make a scientific contribution to the follow-up of these valves. These patients will be compared to patients who have benefited from the implantation of traditional bioprostheses.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Retrospectively included all patients examined since
- •Patients who have aortic valve surgery from the Cardiac Surgery Department of the University Hospital of Amiens.
Exclusion Criteria
- •Refusal to participate in the patient.
- •Patients who have previously had aortic valve surgery.
Outcomes
Primary Outcomes
Variation of mortality rate between both groups
Time Frame: 3 months
both groups are : * Patients undergoing surgical aortic valve replacement with new-generation bioprostheses * Patients who received a traditional bioprosthesis